2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Tarjoustasot
NGM - Nordic SME
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 493 | AVA | AVA | ||
| 196 | AVA | AVA | ||
| 18 | AVA | AVA | ||
| 11 | AVA | AVA | ||
| 71 | NON | EAG |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 30.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1.4.So we have reached Q2 and time flies… It is being heavily discussed on Placera these days, everything from missing reporting on design freeze and the time aspect for clinical test vs market release next year to the company desperately needing capital. What do the shareholders here think about a forthcoming emi?
·7.4.Placera is a forum to vent one's feelings. There is no substance in the forum unless one reads those who link real facts with a source, of course, otherwise the rest of the writings there are crap.
·7.4.Awful lot of meaningless junk and frustration there, yes. It has suddenly been a trader stock a couple of times before, so there are probably quite a few who have burned themselves on short-term hope. There are no biotech stocks having good days now without agreements being in place. This is not about Prolight but generally in many markets.
·1.4.Most things point in one direction but the price points in a completely wrong direction. That doesn't sit well.- ·26.3.It seems that the algos have full control over the price
- ·25.3.BRAINBox is far advanced in TBI diagnostics They have a large pivotal study (HeadSMART II) with over 2,000 patients, which is used as a basis for FDA approval of their TBI test. They also have parallel studies for the elderly and children. This is therefore a company with real clinical data behind it. They have funding and support BRAINBox has raised over 30 million USD, including support from NIH, and works with recognized clinical environments. What is unique for Prolight is that BRAINBox finances the entire next phase They themselves pay for the evaluation of three biomarkers on the Psyros-platform in a 260-patient biobank study. That only happens if the technology actually delivers. Prolight itself says that this strengthens partner dialogues In the message it states that the results from the collaboration “strengthen our position in ongoing and future partner discussions”. That does not mean that an agreement is guaranteed – but it means that dialogues are actually ongoing, and that the data from BRAINBox is actively used in these conversations. What does this mean for us who follow the case? The most important thing is that Psyros not only looks good on troponin, but also works on completely different biomarkers – and that is validated by an external party. This builds technology value and increases the probability that Prolight will not stand alone in the next step.·25.3.Exclusively positive, and for me, this came as a positive surprise. There are many ways to interpret the information that was presented yesterday, and personally, I believe that a potential partner might be a bit further in the future than first anticipated. I am absolutely sure that it will happen, but I had probably thought that this was relatively imminent. The reason is the statement «ongoing and future partner discussions. It's not done with a stroke of a pen, but a longer process with several phases. I don't know how far they have come as of today, and I hope that information about this will come continuously. I would have liked a bit more tangible information from the company regarding this. I understand NDAs etc., but a bit more specifically about where they are in the process would have been nice. I am bullish, but at the same time a bit impatient.·25.3.One never knows, and this was extremely positive. There is very little doubt that they are having ongoing discussions with several, and I bet all the big ones are in place. Normally, they make their move when they are confident. That means from now on or around/after clinical startup. I believe Prolight would gladly want a partner for the clinical process. They are set up for a major player, have signaled large volume in production, and have been awaiting signals for startup . There they just say 2026. I believe that is very deliberate. This can undoubtedly be the trigger to initiate the next step for ABBOT, ROCHE, BIOMerx or Fischer. I have a good feeling that this was what was needed to rip off the bandage. None of these would not want Prolight in their portfolio if they are confident that they can deliver equally high quality in volume.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1.4.So we have reached Q2 and time flies… It is being heavily discussed on Placera these days, everything from missing reporting on design freeze and the time aspect for clinical test vs market release next year to the company desperately needing capital. What do the shareholders here think about a forthcoming emi?·7.4.Placera is a forum to vent one's feelings. There is no substance in the forum unless one reads those who link real facts with a source, of course, otherwise the rest of the writings there are crap.·7.4.Awful lot of meaningless junk and frustration there, yes. It has suddenly been a trader stock a couple of times before, so there are probably quite a few who have burned themselves on short-term hope. There are no biotech stocks having good days now without agreements being in place. This is not about Prolight but generally in many markets.
- ·1.4.Most things point in one direction but the price points in a completely wrong direction. That doesn't sit well.
- ·26.3.It seems that the algos have full control over the price
- ·25.3.BRAINBox is far advanced in TBI diagnostics They have a large pivotal study (HeadSMART II) with over 2,000 patients, which is used as a basis for FDA approval of their TBI test. They also have parallel studies for the elderly and children. This is therefore a company with real clinical data behind it. They have funding and support BRAINBox has raised over 30 million USD, including support from NIH, and works with recognized clinical environments. What is unique for Prolight is that BRAINBox finances the entire next phase They themselves pay for the evaluation of three biomarkers on the Psyros-platform in a 260-patient biobank study. That only happens if the technology actually delivers. Prolight itself says that this strengthens partner dialogues In the message it states that the results from the collaboration “strengthen our position in ongoing and future partner discussions”. That does not mean that an agreement is guaranteed – but it means that dialogues are actually ongoing, and that the data from BRAINBox is actively used in these conversations. What does this mean for us who follow the case? The most important thing is that Psyros not only looks good on troponin, but also works on completely different biomarkers – and that is validated by an external party. This builds technology value and increases the probability that Prolight will not stand alone in the next step.·25.3.Exclusively positive, and for me, this came as a positive surprise. There are many ways to interpret the information that was presented yesterday, and personally, I believe that a potential partner might be a bit further in the future than first anticipated. I am absolutely sure that it will happen, but I had probably thought that this was relatively imminent. The reason is the statement «ongoing and future partner discussions. It's not done with a stroke of a pen, but a longer process with several phases. I don't know how far they have come as of today, and I hope that information about this will come continuously. I would have liked a bit more tangible information from the company regarding this. I understand NDAs etc., but a bit more specifically about where they are in the process would have been nice. I am bullish, but at the same time a bit impatient.·25.3.One never knows, and this was extremely positive. There is very little doubt that they are having ongoing discussions with several, and I bet all the big ones are in place. Normally, they make their move when they are confident. That means from now on or around/after clinical startup. I believe Prolight would gladly want a partner for the clinical process. They are set up for a major player, have signaled large volume in production, and have been awaiting signals for startup . There they just say 2026. I believe that is very deliberate. This can undoubtedly be the trigger to initiate the next step for ABBOT, ROCHE, BIOMerx or Fischer. I have a good feeling that this was what was needed to rip off the bandage. None of these would not want Prolight in their portfolio if they are confident that they can deliver equally high quality in volume.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
NGM - Nordic SME
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 493 | AVA | AVA | ||
| 196 | AVA | AVA | ||
| 18 | AVA | AVA | ||
| 11 | AVA | AVA | ||
| 71 | NON | EAG |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 30.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
45 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 30.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1.4.So we have reached Q2 and time flies… It is being heavily discussed on Placera these days, everything from missing reporting on design freeze and the time aspect for clinical test vs market release next year to the company desperately needing capital. What do the shareholders here think about a forthcoming emi?·7.4.Placera is a forum to vent one's feelings. There is no substance in the forum unless one reads those who link real facts with a source, of course, otherwise the rest of the writings there are crap.·7.4.Awful lot of meaningless junk and frustration there, yes. It has suddenly been a trader stock a couple of times before, so there are probably quite a few who have burned themselves on short-term hope. There are no biotech stocks having good days now without agreements being in place. This is not about Prolight but generally in many markets.
- ·1.4.Most things point in one direction but the price points in a completely wrong direction. That doesn't sit well.
- ·26.3.It seems that the algos have full control over the price
- ·25.3.BRAINBox is far advanced in TBI diagnostics They have a large pivotal study (HeadSMART II) with over 2,000 patients, which is used as a basis for FDA approval of their TBI test. They also have parallel studies for the elderly and children. This is therefore a company with real clinical data behind it. They have funding and support BRAINBox has raised over 30 million USD, including support from NIH, and works with recognized clinical environments. What is unique for Prolight is that BRAINBox finances the entire next phase They themselves pay for the evaluation of three biomarkers on the Psyros-platform in a 260-patient biobank study. That only happens if the technology actually delivers. Prolight itself says that this strengthens partner dialogues In the message it states that the results from the collaboration “strengthen our position in ongoing and future partner discussions”. That does not mean that an agreement is guaranteed – but it means that dialogues are actually ongoing, and that the data from BRAINBox is actively used in these conversations. What does this mean for us who follow the case? The most important thing is that Psyros not only looks good on troponin, but also works on completely different biomarkers – and that is validated by an external party. This builds technology value and increases the probability that Prolight will not stand alone in the next step.·25.3.Exclusively positive, and for me, this came as a positive surprise. There are many ways to interpret the information that was presented yesterday, and personally, I believe that a potential partner might be a bit further in the future than first anticipated. I am absolutely sure that it will happen, but I had probably thought that this was relatively imminent. The reason is the statement «ongoing and future partner discussions. It's not done with a stroke of a pen, but a longer process with several phases. I don't know how far they have come as of today, and I hope that information about this will come continuously. I would have liked a bit more tangible information from the company regarding this. I understand NDAs etc., but a bit more specifically about where they are in the process would have been nice. I am bullish, but at the same time a bit impatient.·25.3.One never knows, and this was extremely positive. There is very little doubt that they are having ongoing discussions with several, and I bet all the big ones are in place. Normally, they make their move when they are confident. That means from now on or around/after clinical startup. I believe Prolight would gladly want a partner for the clinical process. They are set up for a major player, have signaled large volume in production, and have been awaiting signals for startup . There they just say 2026. I believe that is very deliberate. This can undoubtedly be the trigger to initiate the next step for ABBOT, ROCHE, BIOMerx or Fischer. I have a good feeling that this was what was needed to rip off the bandage. None of these would not want Prolight in their portfolio if they are confident that they can deliver equally high quality in volume.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
NGM - Nordic SME
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 493 | AVA | AVA | ||
| 196 | AVA | AVA | ||
| 18 | AVA | AVA | ||
| 11 | AVA | AVA | ||
| 71 | NON | EAG |
Välittäjätilasto
Dataa ei löytynyt